Leaders to announce licensing of UT Health Science Center intellectual property to Rapamycin Holdings Inc.
December 5, 2012
etails concerning the licensing of rapamycin-related intellectual property developed at the UT Health Science Center San Antonio to an emerging spin-out company, Rapamycin Holdings Inc. Rapamycin, a drug federally approved to suppress organ rejection, continues to be studied for its potential to slow the aging process and its efficacy in treating age-related diseases.
December 4, 2012
The 35th annual CTRC-AACR San Antonio Breast Cancer Symposium, where close to 7,500 researchers, clinicians and advocates from around the world are gathering to present and hear about the latest research, trends and topics of discussion in breast cancer, including drug trials and treatment methods.
December 1, 2012
In a free Dec. 8 public lecture, Ian M. Thompson Jr., M.D., will discuss the latest information in prostate cancer prevention and treatment.
November 29, 2012
Close to 7,500 researchers, clinicians and advocates will gather here next week at one of the largest breast cancer symposiums in the world.
November 28, 2012
Tissue donor’s husband to complete floragraph at Wednesday, Dec. 5, event in Edinburg
November 16, 2012
FDA expands approved use of artificial heart valve to more patients
New affiliation between UT Medicine San Antonio and MinuteClinic will increase access to health care services in San Antonio
November 15, 2012
Clinical collaboration and electronic medical record integration included in agreement
November 14, 2012
Distinguished visiting scientists, San Antonio studies to highlight event
November 12, 2012
Managing those pressures is the focus of the Nov. 8 lecture, part of a monthly lecture series at the Cancer Therapy & Research Center at The University of Texas Health Science Center.
November 12, 2012
The inaugural San Antonio Vaccine Symposium — “Vaccine Antigen Discovery and Vaccine-Induced Immunity” — presented by the San Antonio Vaccine Development (SAVE) Center.